oral semaglutide fda Sets Action Date for Wegovy for Weight Loss Novo says it's submitted obesity

Andrea Russo, Director of Electrophysiology and Arrhythmia Services at Cooper Medical School of Rowan University and immediate past president Heart Rhythm Society, for a discussion about pregnancy and arrhythmia

The glucagon component of Retatrutide may offer a partial protective effect here

Crohns Colitis 17 , 12071216 (2023)

Who can benefit from weight loss injections

Exclusion criteria observed in Phase 2 trials included individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, given the class-level concern with GLP-1 receptor agonists and C-cell tumours in rodent models [8]

A lot of the public discussion around these therapies tends to blur together shortage policy, 503A vs 503B distinctions, FDA framework, operational realities, and patient access considerations